Ocotlan Montoya
Family · Lovington, NMNPI 1679810592
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$639
- AbbVie$620
- Novo Nordisk$603
- AstraZeneca$388
- Ardelyx, Inc.$340
- Lilly USA, LLC$312
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,70299%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,747 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $64,902 |
| MounjaroTirzepatide | 39 | $43,101 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $12,189 |
| LinzessLinaclotide | 13 | $10,426 |
| Olmesartan Medoxomil | 112 | $1,224 |
| Buspirone Hcl | 51 | $1,072 |
| Atorvastatin Calcium | 114 | $884 |
| Pantoprazole Sodium | 135 | $822 |
| Levothyroxine Sodium | 104 | $763 |
| Omeprazole | 46 | $711 |
| Duloxetine Hcl | 23 | $672 |
| Gabapentin | 56 | $581 |
| Rosuvastatin Calcium | 47 | $566 |
| Celecoxib | 39 | $520 |
| FenofibrateFenofibrate Nanocrystallized | 13 | $480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $603 | $64,90268 claims |
| Lilly USA, LLCMounjaro | $312 | $43,10139 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $287 | $12,18913 claims |
| AbbVieLinzess | $620 | $10,42613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Lovington
- Victor NaikLovington$3K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
- Katie BoylanRio Rancho$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.